The Cigna Group (CI) Q2 2025 Financial Results Summary

# The Cigna Group (CI) Q2 2025 Financial Results Summary

**Release Date:** July 31, 2025

The Cigna Group (NYSE: CI) reported strong financial results for the second quarter of 2025, reflecting robust growth across its diversified portfolio. This report highlights key metrics and performance updates for the quarter.

## Financial Highlights

– **Total Revenues:**
– Increased **11%** to **$67.2 billion** in Q2 2025 from **$60.5 billion** in Q2 2024.
– Adjusted revenues were **$67.1 billion**, compared to **$60.5 billion** in the previous year.

– **Shareholders’ Net Income:**
– Reported at **$1.5 billion**, or **$5.71** per share, which compares to **$1.5 billion** (or **$5.45** per share) in Q2 2024, marking a growth of **4.8%** in earnings per share.

– **Adjusted Income from Operations:**
– At **$1.9 billion**, or **$7.20** per share; this shows a slight increase of **1%** compared to **$1.9 billion** (or **$6.72** per share) in the same quarter last year.

– **SG&A Expense Ratios:**
– SG&A expense ratio of **5.1%**, down from **6.1%** in Q2 2024.
– Adjusted SG&A expense ratio improved to **4.9%** from **6.0%**.

– **Medical Care Ratio:**
– The Cigna Healthcare MCR was **83.2%**, compared to **82.3%** in Q2 2024, reflecting higher stop loss medical costs.

## Customer Relationships

– **Total Pharmacy Customers:** Increased to **121.9 million**, up **3%** from **December 31, 2024**.
– **Total Medical Customers:** Decreased to **18 million**, marking a **6%** reduction influenced by the HCSC transaction; however, customer numbers remained steady excluding this impact.
– **Total Customer Relationships:** Stood at **182.2 million** at the end of June 2025, a **2%** rise from December 2024, excluding the HCSC transaction.

## Segment Performance

1. **Evernorth Health Services:**
– Adjusted revenues increased by **17%** year-over-year to **$57.8 billion**.
– Adjusted income from operations (pre-tax) rose by **5%**.

– **Pharmacy Benefit Services:**
– Revenue surged by **20%**, driven by strong organic growth.
– Adjusted income increased by **2%**.

– **Specialty and Care Services:**
– Revenue growth of **13%** was achieved.
– Adjusted income improved by **7%**.

2. **Cigna Healthcare:**
– Adjusted revenues decreased by **18%** predominantly due to the HCSC transaction.
– Adjusted income from operations declined **9%**, mainly linked to a higher MCR.
– Without the transaction’s impact, revenues would have increased by **7%** due to premium rate increases.

## Outlook for 2025

– The Cigna Group reaffirms its outlook of at least **$29.60** per share for adjusted income from operations.
– The outlook is inclusive of anticipated share repurchases and expected dividends for the year ending December 31, 2025.

## Dividend and Share Repurchase

– The company is expecting to implement share repurchases and anticipate dividends as part of their 2025 outlook, although specific amounts or timings have not been disclosed.

## Conclusion

Overall, The Cigna Group’s Q2 2025 results demonstrate a strong operational performance with notable revenue growth and adjusted income stability, alongside anticipated strategic investments in share repurchases and dividends for the upcoming year.

Here are the extracted tables from the press release:

### CONDENSED CONSOLIDATED STATEMENTS OF INCOME (in millions)

### CONDENSED CONSOLIDATED BALANCE SHEETS (in millions)

These tables reflect the data structure and formatting as presented in the original document, with minor adjustments made for table consistency and clarity.